Compile Data Set for Download or QSAR
maximum 50k data
Found 4222 with Last Name = 'wiles' and Initial = 'ja'
TargetDNA gyrase subunit A/B(Escherichia coli (strain K12))
Achillion Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50178926(9-cyclopropyl-6-fluoro-7-(piperazin-1-yl)isothiazo...)
Affinity DataIC50:  100nMAssay Description:Inhibitory activity against wild type Escherichia coli gyraseMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetDNA gyrase subunit A/B(Escherichia coli (strain K12))
Achillion Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50178928(7-(3-(aminomethyl)phenyl)-9-cyclopropyl-6-fluorois...)
Affinity DataIC50:  100nMAssay Description:Inhibitory activity against wild type Escherichia coli gyraseMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetDNA gyrase subunit A/B(Escherichia coli (strain K12))
Achillion Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50178922(7-(4-(aminomethyl)phenyl)-9-cyclopropyl-6-fluorois...)
Affinity DataIC50:  100nMAssay Description:Inhibitory activity against wild type Escherichia coli gyraseMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetDNA gyrase subunit A/B(Escherichia coli (strain K12))
Achillion Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50180009(7-(2,6-dimethylpyridin-4-yl)-9-ethyl-1-thia-2,4a-d...)
Affinity DataIC50:  200nMAssay Description:Inhibition of DNA gyrase supercoiling in Escherichia coli ATCC 25922More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetDNA topoisomerase 4 subunit A(Staphylococcus aureus)
Achillion Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50178928(7-(3-(aminomethyl)phenyl)-9-cyclopropyl-6-fluorois...)
Affinity DataIC50:  200nMAssay Description:Inhibitory activity against wild type Staphylococcus aureus topoisomerase 4More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetDNA gyrase subunit A/B(Escherichia coli (strain K12))
Achillion Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50178924(9-cyclopropyl-6-fluoro-7-(3-hydroxyphenyl)isothiaz...)
Affinity DataIC50:  200nMAssay Description:Inhibitory activity against wild type Escherichia coli gyraseMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetDNA gyrase subunit A/B(Escherichia coli (strain K12))
Achillion Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM21690(1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,...)
Affinity DataIC50:  300nMAssay Description:Inhibition of DNA gyrase supercoiling in Escherichia coli ATCC 25922More data for this Ligand-Target Pair
In DepthDetails ArticlePubMedDrugBank

TargetDNA gyrase subunit A/B(Escherichia coli (strain K12))
Achillion Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50131428(1-Cyclopropyl-6-fluoro-8-methoxy-7-(1S,7aS)-octahy...)
Affinity DataIC50:  300nMAssay Description:Inhibitory activity against wild type Escherichia coli gyraseMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetDNA gyrase subunit A/B(Escherichia coli (strain K12))
Achillion Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50178923(7-(3-amino-4-fluorophenyl)-9-cyclopropyl-6-fluoroi...)
Affinity DataIC50:  300nMAssay Description:Inhibitory activity against wild type Escherichia coli gyraseMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetDNA gyrase subunit A/B(Escherichia coli (strain K12))
Achillion Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM21690(1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,...)
Affinity DataIC50:  300nMAssay Description:Inhibitory activity against wild type Escherichia coli gyraseMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMedDrugBank

TargetDNA gyrase subunit A/B(Escherichia coli (strain K12))
Achillion Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50178919(7-(4-aminophenyl)-9-cyclopropyl-6-fluoroisothiazol...)
Affinity DataIC50:  300nMAssay Description:Inhibitory activity against wild type Escherichia coli gyraseMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetDNA topoisomerase 4 subunit A(Staphylococcus aureus)
Achillion Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50178917((S,Z)-7-(3-(aminomethyl)-4-(methoxyimino)pyrrolidi...)
Affinity DataIC50:  300nMAssay Description:Inhibitory activity against wild type Staphylococcus aureus topoisomerase 4More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetDNA gyrase subunit A/B(Escherichia coli (strain K12))
Achillion Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50180011(9-ethyl-7-pyridin-4-yl-1-thia-2,4a-diaza-cyclopent...)
Affinity DataIC50:  400nMAssay Description:Inhibition of DNA gyrase supercoiling in Escherichia coli ATCC 25922More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetDNA gyrase subunit A/B(Escherichia coli (strain K12))
Achillion Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50117914(1-Cyclopropyl-1,4-dihydro-6-fluoro-8-methoxy-7-(3-...)
Affinity DataIC50:  500nMAssay Description:Inhibitory activity against wild type Escherichia coli gyraseMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetDNA topoisomerase 4 subunit A(Staphylococcus aureus)
Achillion Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50178926(9-cyclopropyl-6-fluoro-7-(piperazin-1-yl)isothiazo...)
Affinity DataIC50:  500nMAssay Description:Inhibitory activity against wild type Staphylococcus aureus topoisomerase 4More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetDNA gyrase subunit A/B(Escherichia coli (strain K12))
Achillion Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50178918(9-cyclopropyl-6-fluoro-7-(3-(hydroxymethyl)phenyl)...)
Affinity DataIC50:  500nMAssay Description:Inhibitory activity against wild type Escherichia coli gyraseMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetDNA topoisomerase 4 subunit A(Staphylococcus aureus)
Achillion Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50178912(9-cyclopropyl-6-fluoro-7-(pyridin-3-yl)isothiazolo...)
Affinity DataIC50:  500nMAssay Description:Inhibitory activity against Staphylococcus aureus ATCC 29213 wild type Topo 4More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetDNA gyrase subunit A/B(Escherichia coli (strain K12))
Achillion Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50178917((S,Z)-7-(3-(aminomethyl)-4-(methoxyimino)pyrrolidi...)
Affinity DataIC50:  500nMAssay Description:Inhibitory activity against wild type Escherichia coli gyraseMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetDNA gyrase subunit A/B(Escherichia coli (strain K12))
Achillion Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50045000((NFLX)1-Ethyl-6-fluoro-4-oxo-7-piperazin-1-yl-1,4-...)
Affinity DataIC50:  600nMAssay Description:Inhibition of DNA gyrase supercoiling in Escherichia coli ATCC 25922More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetDNA gyrase subunit A/B(Staphylococcus aureus)
Achillion Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50330327((R)-7-(3-(2-aminopropan-2-yl)pyrrolidin-1-yl)-9-cy...)
Affinity DataIC50:  680nMAssay Description:Inhibition of wild-type Staphylococcus aureus DNA gyrase assessed as inhibition of supercoiling of pBR322 DNA after 60 min by gel electrophoresis ass...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetDNA gyrase subunit A/B(Staphylococcus aureus)
Achillion Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50483850(CHEMBL1774147)
Affinity DataIC50:  680nMAssay Description:Inhibition of wild-type Staphylococcus aureus DNA gyrase assessed as inhibition of supercoiling of pBR322 DNA after 60 min by gel electrophoresis ass...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetDNA topoisomerase 4 subunit A(Staphylococcus aureus)
Achillion Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50178913(7-(6-(aminomethyl)pyridin-3-yl)-9-cyclopropyl-6-fl...)
Affinity DataIC50:  700nMAssay Description:Inhibitory activity against Staphylococcus aureus ATCC 29213 wild type Topo 4More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetDNA gyrase subunit A/B(Escherichia coli (strain K12))
Achillion Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50178925(9-cyclopropyl-6-fluoro-7-(3-(piperidin-2-yl)phenyl...)
Affinity DataIC50:  700nMAssay Description:Inhibitory activity against wild type Escherichia coli gyraseMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetDNA topoisomerase 4 subunit A(Staphylococcus aureus)
Achillion Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50131428(1-Cyclopropyl-6-fluoro-8-methoxy-7-(1S,7aS)-octahy...)
Affinity DataIC50:  800nMAssay Description:Inhibitory activity against wild type Staphylococcus aureus topoisomerase 4More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetDNA topoisomerase 4 subunit A(Staphylococcus aureus)
Achillion Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50131428(1-Cyclopropyl-6-fluoro-8-methoxy-7-(1S,7aS)-octahy...)
Affinity DataIC50:  800nMAssay Description:Inhibitory activity against Staphylococcus aureus ATCC 29213 wild type Topo 4More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetDNA gyrase subunit A/B(Escherichia coli (strain K12))
Achillion Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50178921(9-cyclopropyl-6-fluoro-7-(4-hydroxyphenyl)isothiaz...)
Affinity DataIC50:  800nMAssay Description:Inhibitory activity against wild type Escherichia coli gyraseMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetDNA gyrase subunit A/B(Escherichia coli (strain K12))
Achillion Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50178916(9-cyclopropyl-6-fluoro-7-(4-(hydroxymethyl)phenyl)...)
Affinity DataIC50:  900nMAssay Description:Inhibitory activity against wild type Escherichia coli gyraseMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetComplement factor D(Homo sapiens (Human))
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM109055(US9695205, 1)
Affinity DataIC50: <1.00E+3nMpH: 7.5 T: 2°CAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM109056(US9695205, 2)
Affinity DataIC50: <1.00E+3nMpH: 7.5 T: 2°CAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM109057(US9695205, 3)
Affinity DataIC50: <1.00E+3nMpH: 7.5 T: 2°CAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM109058(US9695205, 4)
Affinity DataIC50: <1.00E+3nMpH: 7.5 T: 2°CAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM109059(US9695205, 5)
Affinity DataIC50: <1.00E+3nMpH: 7.5 T: 2°CAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM109061(US9695205, 6)
Affinity DataIC50: <1.00E+3nMpH: 7.5 T: 2°CAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM109091(US9695205, 7)
Affinity DataIC50: <1.00E+3nMpH: 7.5 T: 2°CAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM109092(US9695205, 8)
Affinity DataIC50: <1.00E+3nMpH: 7.5 T: 2°CAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM109093(US9695205, 9)
Affinity DataIC50: <1.00E+3nMpH: 7.5 T: 2°CAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM109094(US9695205, 10)
Affinity DataIC50: <1.00E+3nMpH: 7.5 T: 2°CAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM109103(US9695205, 11)
Affinity DataIC50: <1.00E+3nMpH: 7.5 T: 2°CAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM109104(US9695205, 12)
Affinity DataIC50: <1.00E+3nMpH: 7.5 T: 2°CAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM109178(US9695205, 13)
Affinity DataIC50: <1.00E+3nMpH: 7.5 T: 2°CAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM109199(US9695205, 14)
Affinity DataIC50: <1.00E+3nMpH: 7.5 T: 2°CAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM109358(US9695205, 15)
Affinity DataIC50: <1.00E+3nMpH: 7.5 T: 2°CAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM109385(US9695205, 16)
Affinity DataIC50: <1.00E+3nMpH: 7.5 T: 2°CAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM109391(US9695205, 17)
Affinity DataIC50: <1.00E+3nMpH: 7.5 T: 2°CAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM109393(US9695205, 18)
Affinity DataIC50: <1.00E+3nMpH: 7.5 T: 2°CAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM109466(US9695205, 19)
Affinity DataIC50: <1.00E+3nMpH: 7.5 T: 2°CAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM109468(US9695205, 20)
Affinity DataIC50: <1.00E+3nMpH: 7.5 T: 2°CAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM109469(US9695205, 21)
Affinity DataIC50: <1.00E+3nMpH: 7.5 T: 2°CAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM109544(US9695205, 22)
Affinity DataIC50: <1.00E+3nMpH: 7.5 T: 2°CAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM109545(US9695205, 23)
Affinity DataIC50: <1.00E+3nMpH: 7.5 T: 2°CAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In DepthDetails US Patent
Displayed 1 to 50 (of 4222 total ) | Next | Last >>
Jump to: